<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34881506</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5829</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Veterinary and comparative oncology</Title>
          <ISOAbbreviation>Vet Comp Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells.</ArticleTitle>
        <Pagination>
          <StartPage>437</StartPage>
          <EndPage>448</EndPage>
          <MedlinePgn>437-448</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/vco.12789</ELocationID>
        <Abstract>
          <AbstractText>Canine mammary tumours (CMTs) are the most common neoplasms in intact bitches, and few chemotherapeutic options are available for highly invasive and metastatic tumours. Recent studies have shown the potential involvement of dysregulated Hippo signalling in CMT development and progression. Statins can activate the Hippo pathway by blocking protein geranylgeranylation (GGylation), resulting in decreased expression and activity of the transcriptional co-activators YAP and TAZ. In this study, we therefore sought to determine if statins could exert anti-cancer effects in CMT cells. Our results demonstrate that Atorvastatin and Fluvastatin are cytotoxic to two CMT cell lines (CMT9 and CMT47), with ED50 values ranging from 0.95 to 23.5 μM. Both statins acted to increase apoptosis and promote cell cycle arrest. Both statins also decreased YAP and TAZ expression and reduced the mRNA levels of key Hippo transcriptional target genes known to be involved in breast cancer progression and chemoresistance (CYR61, CTGF and RHAMM). Moreover, both statins effectively inhibited cell migration and anchorage independent growth, but did not influence matrix invasion. Taken together, our results demonstrate for the first time that statins act upon the Hippo pathway in CMT cells to counteract several molecular and cellular hallmarks of cancer. These findings suggest that targeting the Hippo pathway with statins represents a novel and promising approach for the treatment canine mammary gland cancers.</AbstractText>
          <CopyrightInformation>© 2021 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vigneau</LastName>
            <ForeName>Anne-Laurence</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>Département de Pathologie et de Microbiologie, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rico</LastName>
            <ForeName>Charlène</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Département de Biomédecine Vétérinaire, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boerboom</LastName>
            <ForeName>Derek</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Département de Biomédecine Vétérinaire, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paquet</LastName>
            <ForeName>Marilène</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-3562-4636</Identifier>
            <AffiliationInfo>
              <Affiliation>Département de Pathologie et de Microbiologie, Faculté de médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Vet Comp Oncol</MedlineTA>
        <NlmUniqueID>101185242</NlmUniqueID>
        <ISSNLinking>1476-5810</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004283" MajorTopicYN="Y">Dog Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015674" MajorTopicYN="Y">Mammary Neoplasms, Animal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">YAP and TAZ</Keyword>
        <Keyword MajorTopicYN="N">dogs</Keyword>
        <Keyword MajorTopicYN="N">hippo pathway</Keyword>
        <Keyword MajorTopicYN="N">hydroxymethylglutaryl-CoA reductase inhibitors</Keyword>
        <Keyword MajorTopicYN="N">mammary neoplasms</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>7</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34881506</ArticleId>
        <ArticleId IdType="doi">10.1111/vco.12789</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Merlo DF, Rossi L, Pellegrino C, et al. Cancer incidence in pet dogs: findings of the animal tumor registry of Genoa. Italy J Vet Intern Med. 2008;22(4):976-984. doi:10.1111/j.1939-1676.2008.0133.x</Citation>
        </Reference>
        <Reference>
          <Citation>Moe L. Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl. 2001;57:439-443.</Citation>
        </Reference>
        <Reference>
          <Citation>Vascellari M, Capello K, Carminato A, Zanardello C, Baioni E, Mutinelli F. Incidence of mammary tumors in the canine population living in the Veneto region (northeastern Italy): risk factors and similarities to human breast cancer. Prev Vet Med. 2016;126:183-189. doi:10.1016/j.prevetmed.2016.02.008</Citation>
        </Reference>
        <Reference>
          <Citation>Salas Y, Marquez A, Diaz D, Romero L. Epidemiological study of mammary tumors in female dogs diagnosed during the period 2002-2012: a growing animal health problem. PLoS One. 2015;10(5):e0127381. doi:10.1371/journal.pone.0127381</Citation>
        </Reference>
        <Reference>
          <Citation>Sorenmo KU, Kristiansen VM, Cofone MA, et al. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol. 2009;7(3):162-172. doi:10.1111/j.1476-5829.2009.00184.x</Citation>
        </Reference>
        <Reference>
          <Citation>Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gartner F, Gruber AD. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol. 2011;48(1):98-116. doi:10.1177/0300985810390826</Citation>
        </Reference>
        <Reference>
          <Citation>Sorenmo KU, Worley D, Zappulli V. Tumors of the mammary gland. Withrow &amp; MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2020:842.</Citation>
        </Reference>
        <Reference>
          <Citation>GoldSchmidt M, Shofer FS, Smelstoys JA. Neoplastic lesions of the mammary gland. In: Mohr U, Carlton WW, Dungworth DL, et al., eds. Pathobiology of the Aging Dog. 1st ed. Iowa State University Press; 2001.</Citation>
        </Reference>
        <Reference>
          <Citation>Stratmann N, Failing K, Richter A, Wehrend A. Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg. 2008;37(1):82-86. doi:10.1111/j.1532-950X.2007.00351.x</Citation>
        </Reference>
        <Reference>
          <Citation>Sleeckx N, de Rooster H, Veldhuis Kroeze EJ, Van Ginneken C, Van Brantegem L. Canine mammary tumours, an overview. Reprod Domest Anim. 2011;46(6):1112-1131. doi:10.1111/j.1439-0531.2011.01816.x</Citation>
        </Reference>
        <Reference>
          <Citation>Karayannopoulou M. Recent advances on canine mammary cancer chemotherapy: a review of studies from 2000 to date. Revue Méd Vét. 2016;167(7-8):192-200.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldschmidt M, Pena L, Zappulli V. Tumors of the mammary gland. Tumors in Domestic Animals. John Wiley &amp; Sons Inc.; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM. Canine mammary epithelial neoplasms: biologic implications of morphologic characteristics assessed in 232 dogs. Vet Pathol. 1983;20(2):127-142. doi:10.1177/030098588302000201</Citation>
        </Reference>
        <Reference>
          <Citation>Marconato L, Lorenzo RM, Abramo F, Ratto A, Zini E. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol. 2008;6(2):90-101. doi:10.1111/j.1476-5829.2007.00143.x</Citation>
        </Reference>
        <Reference>
          <Citation>Cassali G, Damasceno K, Bertagnolli A, Estrela-Lima A, et al. Consensus regarding the diagnosis, prognosis and treatment of canine mammary tumors: benign mixed tumors, carcinomas in mixed tumors and carcinosarcomas. Braz J Vet Pathol. 2017;10(3):87-99.</Citation>
        </Reference>
        <Reference>
          <Citation>Harvey KF, Pfleger CM, Hariharan IK. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114(4):457-467. doi:10.1016/s0092-8674(03)00557-9</Citation>
        </Reference>
        <Reference>
          <Citation>Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120-1133. doi:10.1016/j.cell.2007.07.019</Citation>
        </Reference>
        <Reference>
          <Citation>Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73-79. doi:10.1038/nrc3876</Citation>
        </Reference>
        <Reference>
          <Citation>Wu L, Yang X. Targeting the hippo pathway for breast cancer therapy. Cancer. 2018;10(11):422. doi:10.3390/cancers10110422</Citation>
        </Reference>
        <Reference>
          <Citation>Lin KC, Park HW, Guan K-L. Regulation of the hippo pathway transcription factor TEAD. Trends Biochem Sci. 2017;42(11):862-872. doi:10.1016/j.tibs.2017.09.003</Citation>
        </Reference>
        <Reference>
          <Citation>Cordenonsi M, Zanconato F, Azzolin L, et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759-772. doi:10.1016/j.cell.2011.09.048</Citation>
        </Reference>
        <Reference>
          <Citation>Park JH, Shin JE, Park HW. The role of hippo pathway in cancer stem cell biology. Mol Cells. 2018;41(2):83-92. doi:10.14348/molcells.2018.2242</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Wu Y, Wang H, et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A. 2014;111(1):E89-E98. doi:10.1073/pnas.1319190110</Citation>
        </Reference>
        <Reference>
          <Citation>Huang J, Wu S, Barrera J, Matthews K, Pan D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell. 2005;122(3):421-434. doi:10.1016/j.cell.2005.06.007</Citation>
        </Reference>
        <Reference>
          <Citation>Wierzbicki PM, Rybarczyk A. The Hippo pathway in colorectal cancer. Folia Histochem Cytobiol. 2015;53(2):105-119. doi:10.5603/FHC.a2015.0015</Citation>
        </Reference>
        <Reference>
          <Citation>Qiao Y, Li T, Zheng S, Wang H. The Hippo pathway as a drug target in gastric cancer. Cancer Lett. 2018;420:14-25. doi:10.1016/j.canlet.2018.01.062</Citation>
        </Reference>
        <Reference>
          <Citation>Salem O, Hansen CG. The hippo pathway in prostate cancer. Cells. 2019;8(4):370. doi:10.3390/cells8040370</Citation>
        </Reference>
        <Reference>
          <Citation>Rico C, Boerboom D, Paquet M. Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours. Vet Comp Oncol. 2018;16(4):630-635. doi:10.1111/vco.12432</Citation>
        </Reference>
        <Reference>
          <Citation>Sammarco A, Gomiero C, Sacchetto R, et al. Wnt/beta-catenin and hippo pathway deregulation in mammary tumors of humans, dogs, and cats. Vet Pathol. 2020;57(6):774-790. doi:10.1177/0300985820948823</Citation>
        </Reference>
        <Reference>
          <Citation>Beffagna G, Sacchetto R, Cavicchioli L, et al. A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours. Vet J. 2016;207:105-111. doi:10.1016/j.tvjl.2015.10.031</Citation>
        </Reference>
        <Reference>
          <Citation>Luu AK, Schott CR, Jones R, et al. An evaluation of TAZ and YAP crosstalk with TGFbeta signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression. BMC Vet Res. 2018;14(1):365. doi:10.1186/s12917-018-1651-5</Citation>
        </Reference>
        <Reference>
          <Citation>Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28(7):2426-2436. doi:10.1128/MCB.01874-07</Citation>
        </Reference>
        <Reference>
          <Citation>Bartucci M, Dattilo R, Moriconi C, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015;34(6):681-690. doi:10.1038/onc.2014.5</Citation>
        </Reference>
        <Reference>
          <Citation>Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71(7):2728-2738. doi:10.1158/0008-5472.CAN-10-2711</Citation>
        </Reference>
        <Reference>
          <Citation>Guillemette S, Rico C, Godin P, Boerboom D, Paquet M. In vitro validation of the hippo pathway as a pharmacological target for canine mammary gland tumors. J Mammary Gland Biol Neoplasia. 2017;22(3):203-214. doi:10.1007/s10911-017-9384-9</Citation>
        </Reference>
        <Reference>
          <Citation>Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357-366. doi:10.1038/ncb2936</Citation>
        </Reference>
        <Reference>
          <Citation>Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780-791. doi:10.1016/j.cell.2012.06.037</Citation>
        </Reference>
        <Reference>
          <Citation>Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110(3):285-288. doi:10.1172/JCI16421</Citation>
        </Reference>
        <Reference>
          <Citation>Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood). 2004;229(7):567-585. doi:10.1177/153537020422900701</Citation>
        </Reference>
        <Reference>
          <Citation>Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W. Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017;140(5):1068-1081. doi:10.1002/ijc.30526</Citation>
        </Reference>
        <Reference>
          <Citation>Crescencio ME, Rodriguez E, Paez A, Masso FA, Montano LF, Lopez-Marure R. Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells. Int J Biomed Sci. 2009;5(4):411-420.</Citation>
        </Reference>
        <Reference>
          <Citation>Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388-2394. doi:10.1200/JCO.2004.02.027</Citation>
        </Reference>
        <Reference>
          <Citation>Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160(15):2363-2368. doi:10.1001/archinte.160.15.2363</Citation>
        </Reference>
        <Reference>
          <Citation>Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt). 2003;12(8):749-756. doi:10.1089/154099903322447710</Citation>
        </Reference>
        <Reference>
          <Citation>Herron CE, Brueckner CC, Chism JP, et al. Toxicokinetics and toxicity of atorvastatin in dogs. Toxicol Appl Pharmacol. 2015;289(1):117-123. doi:10.1016/j.taap.2015.09.008</Citation>
        </Reference>
        <Reference>
          <Citation>Cunningham SM, Rush JE, Freeman LM. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease. J Vet Intern Med. 2013;27(4):985-989. doi:10.1111/jvim.12123</Citation>
        </Reference>
        <Reference>
          <Citation>Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLoS One. 2018;13(5):e0197422. doi:10.1371/journal.pone.0197422</Citation>
        </Reference>
        <Reference>
          <Citation>McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol. 2003;26(4):III32-8. doi:10.1002/clc.4960261507</Citation>
        </Reference>
        <Reference>
          <Citation>Lutful Kabir FM, Agarwal P, Deinnocentes P, Zaman J, Bird AC, Bird RC. Novel frameshift mutation in the p16/INK4A tumor suppressor gene in canine breast cancer alters expression from the p16/INK4A/p14ARF locus. J Cell Biochem. 2013;114(1):56-66. doi:10.1002/jcb.24300</Citation>
        </Reference>
        <Reference>
          <Citation>Sakaguchi Y, Stephens LC, Makino M, et al. Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Cancer Res. 1995;55(22):5459-5464.</Citation>
        </Reference>
        <Reference>
          <Citation>Dludla PV, Jack B, Viraragavan A, et al. A dose-dependent effect of dimethyl sulfoxide on lipid content, cell viability and oxidative stress in 3T3-L1 adipocytes. Toxicol Rep. 2018;5:1014-1020. doi:10.1016/j.toxrep.2018.10.002</Citation>
        </Reference>
        <Reference>
          <Citation>Brauchle E, Thude S, Brucker SY, Schenke-Layland K. Cell death stages in single apoptotic and necrotic cells monitored by Raman microspectroscopy. Sci Rep. 2014;4:4698. doi:10.1038/srep04698</Citation>
        </Reference>
        <Reference>
          <Citation>Abedini A, Zamberlam G, Lapointe E, et al. WNT5a is required for normal ovarian follicle development and antagonizes gonadotropin responsiveness in granulosa cells by suppressing canonical WNT signaling. FASEB J. 2016;30(4):1534-1547. doi:10.1096/fj.15-280313</Citation>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408. doi:10.1006/meth.2001.1262</Citation>
        </Reference>
        <Reference>
          <Citation>Yamaguchi H, Taouk GM. A potential role of YAP/TAZ in the interplay between metastasis and metabolic alterations. Front Oncol. 2020;10:928. doi:10.3389/fonc.2020.00928</Citation>
        </Reference>
        <Reference>
          <Citation>Van Wyhe RD, Rahal OM, Woodward WA. Effect of statins on breast cancer recurrence and mortality: a review. Breast Cancer (Dove Med Press). 2017;9:559-565. doi:10.2147/BCTT.S148080</Citation>
        </Reference>
        <Reference>
          <Citation>Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene. 2002;21(53):8178-8185. doi:10.1038/sj.onc.1205682</Citation>
        </Reference>
        <Reference>
          <Citation>Huang YT, Lan Q, Lorusso G, Duffey N, Ruegg C. The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis. Oncotarget. 2017;8(6):9200-9215. doi:10.18632/oncotarget.13677</Citation>
        </Reference>
        <Reference>
          <Citation>Chen PS, Wang MY, Wu SN, et al. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci. 2007;120(12):2053-2065. doi:10.1242/jcs.03460</Citation>
        </Reference>
        <Reference>
          <Citation>Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci. 1998;111(12):1685-1694.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim HS. Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer. Ann Oncol. 2019;30:i8.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962-1971. doi:10.1101/gad.1664408</Citation>
        </Reference>
        <Reference>
          <Citation>Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001;61(24):8917-8923.</Citation>
        </Reference>
        <Reference>
          <Citation>Wells JE, Howlett M, Cole CH, Kees UR. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. Int J Cancer. 2015;137(3):504-511. doi:10.1002/ijc.28972</Citation>
        </Reference>
        <Reference>
          <Citation>Chien W, O'Kelly J, Lu D, et al. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol. 2011;38(6):1741-1747. doi:10.3892/ijo.2011.985</Citation>
        </Reference>
        <Reference>
          <Citation>Yeger H, Perbal B. CCN family of proteins: critical modulators of the tumor cell microenvironment. J Cell Commun Signal. 2016;10(3):229-240. doi:10.1007/s12079-016-0346-6</Citation>
        </Reference>
        <Reference>
          <Citation>O'Kelly J, Chung A, Lemp N, et al. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol. 2008;33(1):59-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Saglam O, Dai F, Husain S, Zhan Y, Toruner G, Haines GK 3rd. Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ. Hum Pathol. 2014;45(6):1269-1275. doi:10.1016/j.humpath.2014.02.007</Citation>
        </Reference>
        <Reference>
          <Citation>Wang C, Thor AD, Moore DH 2nd, et al. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res. 1998;4(3):567-576.</Citation>
        </Reference>
        <Reference>
          <Citation>Pujana MA, Han JD, Starita LM, et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet. 2007;39(11):1338-1349. doi:10.1038/ng.2007.2</Citation>
        </Reference>
        <Reference>
          <Citation>Mi W, Lin Q, Childress C, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene. 2015;34(24):3095-3106. doi:10.1038/onc.2014.251</Citation>
        </Reference>
        <Reference>
          <Citation>Adams SP, Sekhon SS, Tsang M, Wright JM. Fluvastatin for lowering lipids. Cochrane Database Syst Rev. 2018;3:CD012282. doi:10.1002/14651858.CD012282.pub2</Citation>
        </Reference>
        <Reference>
          <Citation>Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11. doi:10.1016/j.phrs.2014.03.002</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang P, Mukthavaram R, Chao Y, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer. 2014;111(8):1562-1571. doi:10.1038/bjc.2014.431</Citation>
        </Reference>
        <Reference>
          <Citation>Sanchez CA, Rodriguez E, Varela E, et al. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest. 2008;26(7):698-707. doi:10.1080/07357900701874658</Citation>
        </Reference>
        <Reference>
          <Citation>Unknown. Atorvastatin: OMx Personal Health Analytics Inc; 2005. https://go.drugbank.com/drugs/DB01076</Citation>
        </Reference>
        <Reference>
          <Citation>Unknown. Fluvastatin: OMx Personal Health Analytics Inc; 2005. https://go.drugbank.com/drugs/DB01095</Citation>
        </Reference>
        <Reference>
          <Citation>Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A. 1991;88(9):3628-3632. doi:10.1073/pnas.88.9.3628</Citation>
        </Reference>
        <Reference>
          <Citation>Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51(13):3602-3609.</Citation>
        </Reference>
        <Reference>
          <Citation>Wali VB, Bachawal SV, Sylvester PW. Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood). 2009;234(6):639-650. doi:10.3181/0810-RM-300</Citation>
        </Reference>
        <Reference>
          <Citation>Trojan PJ, Bohatch-Junior MS, Otuki MF, et al. Pravastatin induces cell cycle arrest and decreased production of VEGF and bFGF in multiple myeloma cell line. Braz J Biol. 2016;76(1):59-65. doi:10.1590/1519-6984.11914</Citation>
        </Reference>
        <Reference>
          <Citation>Wang G, Cao R, Wang Y, et al. Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARgamma signalling pathway. Sci Rep. 2016;6:35783. doi:10.1038/srep35783</Citation>
        </Reference>
        <Reference>
          <Citation>Kozar K, Kaminski R, Legat M, et al. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol. 2004;24(5):1149-1157.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang ST, Ho HJ, Lin JT, Shieh JJ, Wu CY. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017;8(2):e2626. doi:10.1038/cddis.2016.472</Citation>
        </Reference>
        <Reference>
          <Citation>Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19(21):2548-2556. doi:10.1038/sj.onc.1203551</Citation>
        </Reference>
        <Reference>
          <Citation>Taha Z, Janse van Rensburg HJ, Yang X. The hippo pathway: immunity and cancer. Cancers (Basel). 2018;10(4):94. doi:10.3390/cancers10040094</Citation>
        </Reference>
        <Reference>
          <Citation>Jang W, Kim T, Koo JS, Kim SK, Lim DS. Mechanical cue-induced YAP instructs Skp2-dependent cell cycle exit and oncogenic signaling. EMBO J. 2017;36(17):2510-2528. doi:10.15252/embj.201696089</Citation>
        </Reference>
        <Reference>
          <Citation>He LPH, Wei F, Gao M, Weng Z, Struhl K. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation; 2021. 10.1101/2021.02.18.431832v1</Citation>
        </Reference>
        <Reference>
          <Citation>Wei Z, Jiang X, Qiao H, et al. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells. Cell Signal. 2013;25(4):931-938. doi:10.1016/j.cellsig.2013.01.011</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang L, Chen T, Dou Y, et al. Atorvastatin exerts antileukemia activity via inhibiting mevalonate-YAP Axis in K562 and HL60 cells. Front Oncol. 2019;9:1032. doi:10.3389/fonc.2019.01032</Citation>
        </Reference>
        <Reference>
          <Citation>Chang YC, Wu JW, Wang CW, Jang AC. Hippo signaling-mediated mechanotransduction in cell movement and cancer metastasis. Front Mol Biosci. 2019;6:157. doi:10.3389/fmolb.2019.00157</Citation>
        </Reference>
        <Reference>
          <Citation>Diepenbruck M, Waldmeier L, Ivanek R, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. J Cell Sci. 2014;127(7):1523-1536. doi:10.1242/jcs.139865</Citation>
        </Reference>
        <Reference>
          <Citation>Sanfilippo KM, Keller J, Gage BF, et al. Statins are associated with reduced mortality in multiple myeloma. J Clin Oncol. 2016;34(33):4008-4014. doi:10.1200/JCO.2016.68.3482</Citation>
        </Reference>
        <Reference>
          <Citation>Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol. 2000;279(6):H2649-H2657. doi:10.1152/ajpheart.2000.279.6.H2649</Citation>
        </Reference>
        <Reference>
          <Citation>Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74(1):75-84. doi:10.1016/j.cardiores.2007.01.002</Citation>
        </Reference>
        <Reference>
          <Citation>Walsh KM, Rothwell CE. Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years. Toxicol Pathol. 1999;27(4):395-401. doi:10.1177/019262339902700402</Citation>
        </Reference>
        <Reference>
          <Citation>Murtola TJ, Peltomaa AI, Talala K, et al. Statin use and prostate cancer survival in the Finnish randomized study of screening for prostate cancer. Eur Urol Focus. 2017;3(2-3):212-220. doi:10.1016/j.euf.2016.05.004</Citation>
        </Reference>
        <Reference>
          <Citation>Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-2192. doi:10.1056/NEJMoa043792</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
